2020
Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study
Wu Y, Kwakkenbos L, Henry R, Carrier M, Gagarine M, Harb S, Bourgeault A, Tao L, Carboni-Jiménez A, Negeri Z, Patten S, Bartlett S, Mouthon L, Varga J, Benedetti A, Thombs B, Advisors F, Fortuné C, Gietzen A, Guillot G, Lewis N, Richard M, Sauvé M, Welling J, Fligelstone K, Gottesman K, Leite C, Pérez E, Investigators S, Baron M, Malcarne V, Mayes M, Nielson W, Riggs R, Assassi S, Ells C, van den Ende C, Frech T, Harel D, Hinchcliff M, Hudson M, Johnson S, Larche M, Nguyen C, Pope J, Rannou F, Reyna T, Schouffoer A, Suarez-Almazor M, Agard C, Albert A, Bernstein E, Berthier S, Bissonnette L, Bruns A, Carreira P, Chaigne B, Chung L, Correia C, Denton C, Domsic R, Dunne J, Dunogue B, Farge-Bancel D, Fortin P, Gordon J, Granel-Rey B, Hatron P, Herrick A, Hoa S, Jones N, de B. Fernandes A, Kafaja S, Khalidi N, Launay D, Manning J, Marie I, Martin M, Mekinian A, Melchor S, Nikpour M, Olagne L, Proudman S, Régent A, Rivière S, Robinson D, Rodriguez E, Roux S, Sobanski V, Steen V, Sutton E, Thorne C, Wilcox P, Ayala M, Carboni-Jiménez A, Gagarine M, Nordlund J, Østbø N, Rice D, Turner K, Culos-Reed N, Dyas L, El-Baalbaki G, Hebblethwaite S, Bustamante L, Duchek D, Ellis K. Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. Journal Of Psychosomatic Research 2020, 140: 110314. PMID: 33271402, PMCID: PMC7685938, DOI: 10.1016/j.jpsychores.2020.110314.Peer-Reviewed Original Research
2014
FibronectinEDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor Signaling
Bhattacharyya S, Tamaki Z, Wang W, Hinchcliff M, Hoover P, Getsios S, White ES, Varga J. FibronectinEDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor Signaling. Science Translational Medicine 2014, 6: 232ra50. PMID: 24739758, PMCID: PMC4414050, DOI: 10.1126/scitranslmed.3008264.Peer-Reviewed Original ResearchConceptsToll-like receptor 4Endogenous TLR4 ligandsCutaneous fibrosisTLR4 ligandToll-like receptor signalingProgressive autoimmune diseaseLesional skin biopsiesFibronectin extra domain ATreatment of fibrosisTissue repair responseHallmark of sclerodermaPersistent fibroblast activationExtra domain ATLR4 blockadeAutoimmune diseasesChronic conditionsChronic fibrosisReceptor 4Skin biopsiesFibrotic responseOrganotypic skin equivalentsMultiple organsPotent stimulusSclerodermaFibroblast activation
2011
Validity of two new patient‐reported outcome measures in systemic sclerosis: Patient‐reported outcomes measurement information system 29‐item health profile and functional assessment of chronic illness therapy–dyspnea short form
Hinchcliff M, Beaumont JL, Thavarajah K, Varga J, Chung A, Podlusky S, Carns M, Chang RW, Cella D. Validity of two new patient‐reported outcome measures in systemic sclerosis: Patient‐reported outcomes measurement information system 29‐item health profile and functional assessment of chronic illness therapy–dyspnea short form. Arthritis Care & Research 2011, 63: 1620-1628. PMID: 22034123, PMCID: PMC3205420, DOI: 10.1002/acr.20591.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAgedChronic DiseaseCross-Sectional StudiesDyspneaFemaleHealth StatusHealth Status IndicatorsHumansMaleMichiganMiddle AgedPredictive Value of TestsPrognosisRegistriesReproducibility of ResultsScleroderma, SystemicSelf ReportSeverity of Illness IndexTime FactorsYoung AdultConceptsOutcomes Measurement Information SystemComposite severity scoreMeasurement Information SystemSeverity scorePRO instrumentsPROMIS-29SSc patientsHealth profileFunctional assessmentHealth statusPatient-reported outcome measuresPatient-reported outcome instrumentsRaynaud's phenomenon symptomsSSc disease durationSystemic sclerosis trialMean patient ageNew patient-reported outcome measurePatient-Reported Outcomes Measurement Information SystemPhysical functioning scoresCross-sectional studyDisease severity scoreShort formNew PRO instrumentComplicated scoring systemsDisease durationEvidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps
Tan BK, Li QZ, Suh L, Kato A, Conley DB, Chandra RK, Zhou J, Norton J, Carter R, Hinchcliff M, Harris K, Peters A, Grammer LC, Kern RC, Mohan C, Schleimer RP. Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps. Journal Of Allergy And Clinical Immunology 2011, 128: 1198-1206.e1. PMID: 21996343, PMCID: PMC3384688, DOI: 10.1016/j.jaci.2011.08.037.Peer-Reviewed Original ResearchConceptsPresence of autoantibodiesChronic rhinosinusitisNasal polypsNasal tissueAnti-dsDNA antibody levelsSelf-reactive B cell clonesIgA-secreting plasma cellsB-cell activating factorControl nasal tissueEvidence of autoimmunityAnti-dsDNA IgGB cell clonesPotential of antibodiesAutoantibody microarrayAutoantibody levelsIgA antibodiesSpecific autoantibodiesAntibody levelsSubepithelial depositionAutoimmune diseasesSinonasal tissueControl subjectsInflammatory conditionsRevision surgeryImmunoglobulin production